{"title":"Prospective of healthcare professionals regarding pharmacogenomics","authors":"Anuradha T Deshkar, Sonali B. Rode","doi":"10.4103/epj.epj_175_22","DOIUrl":null,"url":null,"abstract":"Background and objective Pharmacogenomics is an emerging branch and its application in clinical practice will improve healthcare delivery in India. For the promotion and adaptation of pharmacogenomics, we need baseline data from healthcare professionals (HCPs). So, this study was planned to know the prospective of HCPs in India regarding pharmacogenomics. Patients and methods The printed copies of the pretested and validated, single-response or multiple-response self-administered questionnaire, were distributed to the HCPs. There was a total of 19 questions to access knowledge, attitude, and practices regarding pharmacogenomics. Data obtained were entered in Microsoft Excel 2013 spreadsheet for statistical analysis and percentages were calculated for concerned responses. Results Out of 134 responses, 126 responses were found to be eligible for analysis. Seventy-eight (61.9%) participants scored more than or equal to 5 to show above-average knowledge. Ninety (71.4%) participants showed a favorable attitude with a score of more than or equal to 3, while 91 (72.2%) participants scored more than or equal to 3 to show favorable practices regarding pharmacogenomics. Hundred and seven (84.9%) participants believed that pharmacogenomics will lead to more effective pharmacotherapy. Conclusion Participants showed above-average knowledge; favorable attitude, and practice behavior regarding pharmacogenomics. The survey indicates that conducting Information, Education, and Communication activities may help to increase awareness and knowledge, and to promote the adoption and utilization of pharmacogenomics in clinical practice, which will lead to better pharmacological treatment of disease with maximum efficacy and minimum side effects.","PeriodicalId":11568,"journal":{"name":"Egyptian Pharmaceutical Journal","volume":"22 1","pages":"259 - 264"},"PeriodicalIF":0.7000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Egyptian Pharmaceutical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/epj.epj_175_22","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objective Pharmacogenomics is an emerging branch and its application in clinical practice will improve healthcare delivery in India. For the promotion and adaptation of pharmacogenomics, we need baseline data from healthcare professionals (HCPs). So, this study was planned to know the prospective of HCPs in India regarding pharmacogenomics. Patients and methods The printed copies of the pretested and validated, single-response or multiple-response self-administered questionnaire, were distributed to the HCPs. There was a total of 19 questions to access knowledge, attitude, and practices regarding pharmacogenomics. Data obtained were entered in Microsoft Excel 2013 spreadsheet for statistical analysis and percentages were calculated for concerned responses. Results Out of 134 responses, 126 responses were found to be eligible for analysis. Seventy-eight (61.9%) participants scored more than or equal to 5 to show above-average knowledge. Ninety (71.4%) participants showed a favorable attitude with a score of more than or equal to 3, while 91 (72.2%) participants scored more than or equal to 3 to show favorable practices regarding pharmacogenomics. Hundred and seven (84.9%) participants believed that pharmacogenomics will lead to more effective pharmacotherapy. Conclusion Participants showed above-average knowledge; favorable attitude, and practice behavior regarding pharmacogenomics. The survey indicates that conducting Information, Education, and Communication activities may help to increase awareness and knowledge, and to promote the adoption and utilization of pharmacogenomics in clinical practice, which will lead to better pharmacological treatment of disease with maximum efficacy and minimum side effects.